Understanding Tysabri and Progressive Multifocal Leukoencephalopathy: Key Facts for North Carolina Patients

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Targeted Risk Communication

If you or a loved one is taking Tysabri for multiple sclerosis or Crohn's disease, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection. Medical understanding of treatment risks has evolved significantly over the years, with a growing emphasis on balancing therapeutic benefits against potential adverse events. This page provides a clear overview of PML associated with Tysabri, including what the science says about risk factors, symptoms, and monitoring recommendations.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis (MS) and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the John Cunningham virus (JCV). For patients in North Carolina who have developed PML after Tysabri treatment, understanding the medical evidence and legal timelines is critical. The prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning identifies three primary risk factors: the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants. These factors must be weighed against expected benefits when initiating or continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label emphasizes that healthcare professionals should monitor patients for any new signs or symptoms suggestive of PML and that Tysabri dosing should be withheld immediately at the first indication of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically presents with progressive neurological deficits, including cognitive decline, motor weakness, visual disturbances, and speech difficulties. Diagnosis relies on brain MRI findings and detection of JCV DNA in cerebrospinal fluid. The clinical course is often devastating, with most cases leading to severe disability or death. The mechanistic link between Tysabri and PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect reduces immune surveillance, allowing latent JCV to reactivate and cause lytic infection of oligodendrocytes.

Legal Considerations: Statute of Limitations in North Carolina

For patients in North Carolina considering legal action, the statute of limitations for product liability claims involving Tysabri and PML is generally governed by state law. In North Carolina, the statute of limitations for personal injury claims is typically three years from the date the injury was discovered or should have been discovered with reasonable diligence. For PML, the timeline between Tysabri exposure and documented harm can vary. The label reports that herpes infections (encephalitis and meningitis) have occurred "a few months to several years" after starting Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), and similar latency periods are observed for PML. The duration of Tysabri therapy is a known risk factor, with longer exposure increasing PML risk. This means the date of diagnosis—often months or years after starting treatment—is critical for determining when the statute of limitations begins. FDA adverse event reports for Tysabri frequently include neurological symptoms that could overlap with early PML presentation, such as fatigue (19,150 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), balance disorder (5,621 reports), and cognitive disorder (3,478 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These reports underscore the importance of prompt evaluation when new neurological symptoms arise during Tysabri therapy. For patients who later receive a PML diagnosis, the delay between symptom onset and diagnosis may affect legal timelines. Attorney considerations for affected patients include evaluating whether the manufacturer provided adequate warnings about PML risk, whether healthcare providers followed monitoring protocols, and whether the patient's specific risk factors were properly assessed. The boxed warning and TOUCH program requirements create a framework for risk communication, but individual cases may involve questions about informed consent and the adequacy of risk disclosure. Patients should also consider whether their PML diagnosis was timely, as delayed diagnosis can worsen outcomes and may affect legal claims.

Medical Evidence and Risk Factors for Tysabri-Associated PML

The adequacy of warnings regarding Tysabri and PML is a central issue for affected patients. The boxed warning explicitly states the risk and the need for enrollment in the restricted TOUCH Prescribing Program, which requires patients to read a Medication Guide, understand the risks, and sign an enrollment form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether prescribers adequately communicated the magnitude of risk, particularly for patients with multiple risk factors. The label also notes that Tysabri should not be used in combination with immunosuppressants or TNF-alpha inhibitors in Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), and prior immunosuppressant use is a recognized risk factor for PML. In summary, Tysabri-associated PML is a severe adverse event with well-documented risk factors and clinical presentation. For North Carolina patients, the statute of limitations typically runs from the date of PML diagnosis or when symptoms should have been recognized. The medical evidence supports the causal link between Tysabri and PML, and the adequacy of warnings is a key legal consideration. Patients should consult with an attorney experienced in pharmaceutical litigation to assess their specific circumstances and ensure compliance with applicable deadlines.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in North Carolina?

In North Carolina, the statute of limitations for personal injury claims is typically three years from the date the injury was discovered or should have been discovered with reasonable diligence. For PML, this often starts from the date of diagnosis or when symptoms should have been recognized. It is crucial to consult an attorney promptly to ensure compliance with deadlines.

What are the primary risk factors for developing PML while on Tysabri?

The prescribing information identifies three primary risk factors: the presence of anti-JCV antibodies, duration of therapy (longer exposure increases risk), and prior use of immunosuppressants. These factors must be weighed against expected benefits when initiating or continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.